{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:44:50Z","timestamp":1768736690821,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.imlet.2020.04.005","type":"journal-article","created":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T19:21:07Z","timestamp":1586632867000},"page":"44-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro"],"prefix":"10.1016","volume":"223","author":[{"given":"Keyvan","family":"Fallah-Mehrjardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid Reza","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Masoumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Jafarzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hosein","family":"Rostamian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Khakpoor-Koosheh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khadijeh","family":"Alishah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farshid","family":"Noorbakhsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamshid","family":"Hadjati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.imlet.2020.04.005_bib0005","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.imlet.2020.04.005_bib0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.imlet.2020.04.005_bib0015","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1038\/s41467-019-10565-7","article-title":"Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.imlet.2020.04.005_bib0020","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2020.04.005_bib0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-018-0568-6","article-title":"Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.imlet.2020.04.005_bib0030","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark. Res."},{"issue":"6","key":"10.1016\/j.imlet.2020.04.005_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12032-018-1149-9","article-title":"Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors","volume":"35","author":"Jindal","year":"2018","journal-title":"Med. Oncol. (Northwood, Lond., Engl.)"},{"issue":"4","key":"10.1016\/j.imlet.2020.04.005_bib0040","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/bjh.13340","article-title":"CD19 chimeric antigen receptor T cell therapy for haematological malignancies","volume":"169","author":"Ghorashian","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.imlet.2020.04.005_bib0045","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","article-title":"The application of CAR-T cell therapy in hematological malignancies: advantages and challenges","volume":"8","author":"Zhao","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"6","key":"10.1016\/j.imlet.2020.04.005_bib0050","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.imlet.2020.04.005_bib0055","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.imlet.2020.04.005_bib0060","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.imlet.2020.04.005_bib0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41568-018-0081-9","article-title":"The lung microenvironment: an important regulator of tumour growth and metastasis","volume":"19","author":"Altorki","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.005_bib0070","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4049\/jimmunol.1800242","article-title":"Composition and clinical impact of the immunologic tumor microenvironment in oral squamous cell carcinoma","volume":"202","author":"Boxberg","year":"2019","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.imlet.2020.04.005_bib0075","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1541-7786.MCR-14-0028","article-title":"The role of hypoxia and exploitation of the hypoxic environment in hematologic malignancies","volume":"12","author":"Muz","year":"2014","journal-title":"Mol. Cancer Res."},{"issue":"22","key":"10.1016\/j.imlet.2020.04.005_bib0080","doi-asserted-by":"crossref","first-page":"36832","DOI":"10.18632\/oncotarget.15981","article-title":"The hypoxia signalling pathway in haematological malignancies","volume":"8","author":"Irigoyen","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.imlet.2020.04.005_bib0085","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.4049\/jimmunol.0900475","article-title":"Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness","volume":"183","author":"Hilchey","year":"2009","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.005_bib0090","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7150\/jca.5112","article-title":"The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas","volume":"4","author":"Koontongkaew","year":"2013","journal-title":"J. Cancer"},{"key":"10.1016\/j.imlet.2020.04.005_bib0095","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3389\/fimmu.2017.01850","article-title":"Chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications","volume":"8","author":"Mirzaei","year":"2017","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.imlet.2020.04.005_bib0100","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.imlet.2020.04.005_bib0105","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.imlet.2020.04.005_bib0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/bloodadvances.2016000984","article-title":"Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment","volume":"1","author":"Serra","year":"2016","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.imlet.2020.04.005_bib0115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","article-title":"Targeting adenosine for cancer immunotherapy","volume":"6","author":"Leone","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.imlet.2020.04.005_bib0120","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","article-title":"CD39 and CD73 in immunity and inflammation","volume":"19","author":"Antonioli","year":"2013","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.imlet.2020.04.005_bib0125","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fimmu.2016.00109","article-title":"A metabolic immune checkpoint: adenosine in tumor microenvironment","volume":"7","author":"Ohta","year":"2016","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.imlet.2020.04.005_bib0130","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJMra0910283","article-title":"Hypoxia and inflammation","volume":"364","author":"Eltzschig","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2020.04.005_bib0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02517","article-title":"Tumor microenvironment-induced immunometabolic reprogramming of natural killer cells","volume":"9","author":"Chambers","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2020.04.005_bib0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00109","article-title":"A metabolic immune checkpoint: adenosine in tumor microenvironment","volume":"7","author":"Ohta","year":"2016","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.imlet.2020.04.005_bib0145","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317695021","article-title":"Increased efficacy of a dendritic cell-based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor","volume":"39","author":"Arab","year":"2017","journal-title":"Tumour Biol."},{"issue":"2","key":"10.1016\/j.imlet.2020.04.005_bib0150","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3390\/ijms15022024","article-title":"Adenosine receptors: expression, function and regulation","volume":"15","author":"Sheth","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.imlet.2020.04.005_bib0155","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1172\/JCI89455","article-title":"Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy","volume":"127","author":"Beavis","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"Suppl. 1","key":"10.1016\/j.imlet.2020.04.005_bib0160","first-page":"e728","article-title":"Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling","volume":"128","author":"Linnemann","year":"2009","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.imlet.2020.04.005_bib0165","doi-asserted-by":"crossref","first-page":"9207","DOI":"10.1002\/jcp.27599","article-title":"Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells","volume":"234","author":"Mirzaei","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"12","key":"10.1016\/j.imlet.2020.04.005_bib0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082742","article-title":"Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma","volume":"8","author":"Budde","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.imlet.2020.04.005_bib0175","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1158\/2326-6066.CIR-15-0276","article-title":"Preserved activity of CD20-specific chimeric antigen receptor-expressing T cells in the presence of rituximab","volume":"4","author":"Rufener","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.imlet.2020.04.005_bib0180","series-title":"Diagnosis of Sexually Transmitted Diseases","first-page":"381","article-title":"Protocol for the clonal analysis of NK cell effector functions by multi-parameter flow cytometry","author":"Sch\u00f6nberg","year":"2012"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.005_bib0185","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2007-03-081646","article-title":"A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells","volume":"111","author":"Zarek","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.imlet.2020.04.005_bib0190","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.3324\/haematol.2018.195396","article-title":"Updates on the hematologic tumor microenvironment and its therapeutic targeting","volume":"104","author":"Forte","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.imlet.2020.04.005_bib0195","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/14712598.2016.1133582","article-title":"Effect of hypoxia-inducible factors in normal and leukemic stem cell regulation and their potential therapeutic impact","volume":"16","author":"Rouault-Pierre","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.imlet.2020.04.005_bib0200","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41389-017-0011-9","article-title":"The hypoxic tumour microenvironment","volume":"7","author":"Petrova","year":"2018","journal-title":"Oncogenesis"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.005_bib0205","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.4049\/jimmunol.174.2.1073","article-title":"A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells","volume":"174","author":"Lappas","year":"2005","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"5","key":"10.1016\/j.imlet.2020.04.005_bib0210","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","article-title":"Adenosine receptor 2A blockade increases the efficacy of Anti-PD-1 through enhanced antitumor T-cell responses","volume":"3","author":"Beavis","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.imlet.2020.04.005_bib0215","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13046-020-01546-6","article-title":"Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells","volume":"39","author":"Masoumi","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247820300754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247820300754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:37:06Z","timestamp":1759045026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247820300754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":43,"alternative-id":["S0165247820300754"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2020.04.005","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2020.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}